Agencys contribution to the pandemic response PCWP/HCPWP joint - - PowerPoint PPT Presentation

An agency of the European Union

Agency’s contribution to the pandemic response

PCWP/HCPWP joint meeting, 2 June 2020

Presented by: Noël Wathion, Deputy Executive Director, EMA

Classified as public by the European Medicines Agency

EMA COVID-19 Task Force Structure

EMA status reports 1

Communication (internal and external)

COVID-19 Task Force

Work stream 1 Therapeutic Response

Institutional coordination

Work stream 2 Supply Chain Work stream 3 Business Continuity and Impact Work stream 4 Human Resources

Classified as public by the European Medicines Agency

EMA status reports 2

Task Force

• to ensure the Agency’s business continuity in any possible scenario following the outbreak of

COVID-19 infections in Europe

• to oversee work undertaken in the four areas of activities pertaining to the four workstreams
• to routinely inform the Executive Board on its progress

Institutional Coordination

• to steer the work of the Task Force, ensuring alignment with the direction of travel of other

institutions and bodies at operational and political level, in close liaison with the European Commission.

Work Streams

• To facilitate the work of the COVID-19 Task Force
• supported by teams of colleagues responsible for specific activities and deliverables.
• each workstream analyse data, propose solutions and provide outcomes to the Task Force,

where they are further reviewed and sent for final endorsement by the EXB

EMA COVID-19 structure: Mandates per entity

Classified as public by the European Medicines Agency

Communication activities: External

EMA status reports 3

External (Network and Stakeholders):

• Circulation of press releases and Lines To Take (LTT) to the European Medicines Regulatory

Network

• Weekly circulation of outcome of EU ExSG meetings including supporting information to HMA,

EC, CMDx.

• Regular updates on EMA’s website on:
• COVID-19 vaccines and therapeutics
• Availability of medicines during the emergency
• Public health advice
• Guidance to companies
• Press briefing on 14 May 2020

Classified as public by the European Medicines Agency

Any questions?

Temporary visiting address Spark building ● Orlyplein 24 ● 1043 DP Amsterdam ● The Netherlands For deliveries refer to www.ema.europa.eu/how-to-find-us Send us a question via www.ema.europa.eu/contact Telephone +31 (0)88 781 6000

Further information

Follow us on @EMA_News